As a major in vitro diagnostics company, focusing on infectious diseases, bioMérieux develops, manufactures and markets reagents and automated systems designed for medical analyses and product quality control in the agri-food, cosmetics and pharmaceutical industries, as well as the environment. With sales of FRF 3.4 billion in 1999, bioMérieux ranks as the eighth largest biological diagnostics company worldwide. Seventy-five percent of its activity takes place on an international level. Over the last 3 years, bioMérieux has dedicated more than 12% of sales for research and development of new tools aimed at improving disease detection, monitoring and treatment.

Through this investment, bioMérieux provides laboratories and hospitals with innovative solutions that help control healthcare costs and improve patient therapy, supplies industries with increasingly efficient solutions to control the microbiological quality of their products.

bioMérieux maintains its worldwide presence with production and research sites located in France, Italy, the United States and Brazil, and through its 27 subsidiaries and more than 100 distributors.

OUR MISSION
The challenges facing our profession are issues of public health. As many changes are now taking place in the world health environment - a rapid growth in requirements, increasingly tight financial constraints - bioMérieux has taken on the mission of maintaining a front-line position in the worldwide struggle against infectious diseases in clinical and industrial biology.

OUR STRATEGY
To strengthen our worldwide position in the diagnosis of infectious diseases.

To achieve this:

innovate in microbiology, immunoassays and molecular diagnostics, strengthen our worldwide network, improve our operational profitability to free the resources needed to finance our research and international development.

For more information, please visit our website at www.biomerieux.com